HomeQuestion

How would do manage stage II/III Muscle invasive bladder cancer with large cell neuroendocrine histology?

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

Based on NIAGARA data, do you now feel more comfortable offering cisplatin based chemotherapy to patients with impaired renal function?

In patients with muscle-invasive bladder cancer seeking bladder preservation, would positive ctDNA affect your approach to trimodality therapy?

Would you use T-DXd as a first-line agent for a patient who developed early metastatic relapse of HER2+ urothelial cancer shortly after standard perioperative chemo/immunotherapy, over other standard non-targeted treatments?

For patients with modest hyperbilirubinemia (Tbili 2-3) due to chronic liver disease, but otherwise normal liver indices, would you consider still utilizing enfortumab vedotin for metastatic urothelial carcinoma?

What are your top takeaways from ASCO GU 2026?

Evidence Meets Expertise

For Physicians

Mednet AI
Community

Company

About
Careers
Publications
Blog

Support

FAQs
Code of Conduct
AI Community Guidelines
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.